Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 May 18;215:105638. doi: 10.1016/j.antiviral.2023.105638

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2023 The Authors

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

PMC Copyright notice

Fig. 1 — In vivo efficacy of Sotrovimab and Cilgavimab/Tixagévimab against BA.1, BA.2, BQ.1.1 and XBB.1 Omicron variants.

(A) Experimental timeline. (B) Mean lung reduction infectious titer reduction compared to control treated animals and mean serum concentrations of mAbs at 3dpi. (C) Lung infectious titers and (D) viral RNA yields in nasal washes at 3dpi (Data represent mean ± SD of individual data). ****, ***, ** and * symbols indicate that the average value for the group is significantly lower than that of the control treated group with a p-value <0.0001, ranging between 0.0001 and 0.001, 0.001–0.01, and 0.01–0.05, respectively.